Ozanimod

證據等級: L5

預測適應症: 1 個

Ozanimod: From Relapsing Multiple Sclerosis to Progressive Relapsing Multiple Sclerosis

One-Sentence Summary

Ozanimod (ZEPOSIA®) is a selective sphingosine-1-phosphate (S1P) receptor modulator, approved in the US and EU since 2020 for relapsing forms of multiple sclerosis (MS), including relapsing-remitting disease and active secondary progressive disease. The TxGNN model predicts it may be effective for Progressive Relapsing Multiple Sclerosis (PRMS), with 8 clinical trials and 18 publications currently supporting this direction. The overall evidence quality is rated L1, anchored by a completed Phase 3 RCT enrolling 2,494 patients.

Quick Overview

Item	Content
Original Indication	Relapsing forms of multiple sclerosis (FDA approved March 2020; EMA approved May 2020)
Predicted New Indication	Progressive Relapsing Multiple Sclerosis
TxGNN Prediction Score	99.34%
Evidence Level	L1
Italy Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Ozanimod is a next-generation, orally administered S1P receptor modulator that acts as a functional antagonist at receptor subtypes S1PR1 and S1PR5. By binding to S1PR1 on the surface of lymphocytes, it triggers receptor internalization, causing autoreactive T and B lymphocytes to be sequestered in the lymph nodes and unable to cross into the central nervous system. This directly interrupts the neuroinflammatory cascade that drives both relapses and early progressive disability in relapsing MS phenotypes.

The additional modulation of S1PR5 — expressed predominantly on NK cells and CNS oligodendrocytes — provides a mechanistic dimension beyond simple peripheral immunosuppression. S1PR5 activity influences myeloid and NK cell trafficking within the CNS, as well as oligodendrocyte survival and myelin integrity. This dual receptor selectivity is hypothesized to contribute neuroprotective effects in progressive MS, where compartmentalized CNS inflammation is a major driver of disability accumulation not adequately addressed by peripheral-only therapies.

Progressive relapsing MS (PRMS) is characterized by continuous neurological decline from disease onset with superimposed acute relapses — sharing the same inflammatory attack mechanism as RRMS but with added progressive pathology. Since ozanimod's mechanism directly targets the core inflammatory pathway common to all relapsing MS phenotypes, its applicability to PRMS is mechanistically well-grounded. This is further supported by the landmark Phase 3 RADIANCE Part B trial (NCT02576717, n=2,494), which enrolled a broad relapsing MS population that encompassed PRMS subtypes, and by the real-world ORION study (n=9,000) currently generating long-term post-market safety data.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02576717	Phase 3	Completed	2,494	RADIANCE Part B: double-blind, double-dummy RCT of ozanimod vs. IFN-β1a in relapsing MS (including PRMS); provides the highest-level direct efficacy and safety evidence for ozanimod in this population
NCT05605782	N/A	Active, Not Recruiting	9,000	ORION: large post-authorisation, real-world safety study comparing ozanimod vs. other S1P receptor modulators and non-S1P DMTs in RRMS; long-term adverse event surveillance through 2033
NCT06396039	Phase 4	Active, Not Recruiting	84	Single-arm open-label Phase 4 study assessing ozanimod effectiveness and safety specifically in Chinese adults with relapsing MS; provides real-world complement to Phase 3 registration data
NCT05828901	N/A	Recruiting	60	Observational study predicting disease activity and rebound risk in MS patients treated with S1P receptor modulators including ozanimod; directly relevant to stopping/switching risk management
NCT03500328	N/A	Active, Not Recruiting	900	TREAT-MS: pragmatic trial evaluating early aggressive therapy vs. escalation strategy in relapsing MS (n=900); contextualizes ozanimod's positioning within treatment algorithm
NCT03535298	Phase 4	Active, Not Recruiting	800	DELIVER-MS: compares early high-efficacy DMT vs. escalation in relapsing-remitting MS; findings applicable to ozanimod's therapeutic class and strategic placement
NCT04676204	N/A	Enrolling by Invitation	323	STATURE: multi-site observational study measuring treatment burden and medication adherence across 6 oral DMTs including ozanimod; informs patient-centred prescribing decisions
NCT05688436	N/A	Recruiting	1,178	Pregnancy outcomes registry for diroximel fumarate in MS; limited direct ozanimod relevance, but provides safety class context for oral DMTs in women of childbearing age

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38174776	2024	Network Meta-Analysis	Cochrane Database Syst Rev	Updated 2024 Cochrane NMA comparing immunomodulators and immunosuppressants for RRMS; establishes the relative efficacy hierarchy of approved DMTs including ozanimod
39254048	2024	Network Meta-Analysis	Cochrane Database Syst Rev	Cochrane NMA specifically for progressive MS; evaluates relative benefit and safety of immunomodulatory therapies in PMS — the most directly relevant systematic review for the PRMS indication
33287177	2020	Comprehensive Drug Review	Neurology International	Ozanimod-specific review covering disease background, S1P mechanism, Phase 2/3 trial efficacy data, and side-effect profile for relapsing MS
32059809	2020	Regulatory Review	Drugs	First-approval regulatory review of ozanimod (ZEPOSIA®); documents FDA/EMA approval scope, registrational trial results (RADIANCE, SUNFLOWER), and mechanistic basis
36946625	2023	Therapeutic Class Review	Expert Opin Pharmacother	Updated comparative review of S1PR modulators (fingolimod, siponimod, ozanimod, ponesimod); positions ozanimod within the class and summarizes its selectivity advantage
38162670	2023	Pharmacological Review	Frontiers in Immunology	Reviews CNS-bioavailable DMTs; discusses evidence for direct CNS penetration vs. peripheral-only action — directly relevant to the neuroprotection rationale for PRMS
33797705	2021	Drug Class Review	CNS Drugs	Reviews S1PR modulator class mechanism and clinical evidence from fingolimod to ozanimod; contextualizes ozanimod's S1PR1/5 selectivity and improved cardiac safety profile
37638037	2023	Preclinical Study	Frontiers in Immunology	Selective S1PR1/5 modulator shows beneficial effects in a CNS neurodegeneration model; provides preclinical mechanistic support for S1PR5 targeting in progressive MS neuroprotection
31598138	2019	Therapeutic Review	Ther Adv Neurol Disord	Reviews emerging therapeutic strategies for progressive MS including S1PR modulators; highlights the rationale for targeting compartmentalized CNS inflammation in PRMS
41919069	2026	Real-World Evidence	Ther Adv Neurol Disord	MSBase registry comparative effectiveness of anti-CD20 therapies vs. S1P receptor modulators in late-onset MS; provides 2026 real-world performance data relevant to S1PR modulator class

Italy Market Information

No regulatory authorizations for ozanimod are currently on record in Italy per the available data (0 licenses, AIFA query returned no results).

Note: Ozanimod (ZEPOSIA®) holds EMA approval since May 2020 for relapsing forms of MS in adult patients. Local AIFA registration and reimbursement status should be independently confirmed via the official AIFA registry before any formulary or prescribing decisions.

Safety Considerations

Please refer to the package insert for safety information.

Note: Formal safety data (key warnings, contraindications, drug-drug interactions) was not retrievable from the queried sources at the time of this report. As a class effect, S1P receptor modulators are associated with bradycardia/atrioventricular block at initiation, macular oedema, elevated liver enzymes, and increased risk of infections. Prescribers should consult the official ZEPOSIA® Summary of Product Characteristics (SmPC) for complete guidance before initiating therapy.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The completed Phase 3 RADIANCE Part B trial (n=2,494) and the large ongoing real-world ORION safety cohort (n=9,000) provide L1-level evidence for ozanimod in relapsing MS including the PRMS subtype, with mechanistic plausibility strongly supported by the dual S1PR1/5 selectivity profile. The TxGNN model score of 99.34% further corroborates the biological signal, and the 2024 Cochrane NMA for progressive MS provides a rigorous systematic evidence base.

To proceed, the following is needed:

Obtain the full ZEPOSIA® SmPC / package insert to complete warnings, contraindications, and drug interaction review (currently a blocking data gap)
Confirm current AIFA registration and reimbursement eligibility via the official AIFA database
Establish a cardiac monitoring protocol (ECG pre-dose, 6-hour first-dose observation) per class requirements for S1PR modulators
Define an ophthalmologic monitoring schedule for macular oedema risk (baseline exam + follow-up at 3–4 months)
Confirm hepatic function monitoring plan given S1PR modulator hepatotoxicity signals (LFTs at baseline and periodically)
Clarify patient subgroup criteria distinguishing PRMS from RRMS and active SPMS to define the intended clinical implementation population
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.